Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Addicts Therapeutics Half Year 2025 Financial Results Corporate Update Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, please press star 1 and 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 and 1 again. To ask a question via the webcast, please access the Ask a Question tab. Please note that today's conference is being recorded. I would now like to have the conference over to your speaker, Tim Dyer, CEO. Please go ahead, sir. Thank you. Hello, everyone. I'd like to thank you all for attending our half-year 2025 financial results conference call. I'm here with Mikhail Kalinichev, who will provide an update on our R&D programs. I draw your attention to the press release and the financial statements issued yesterday, which are available on the website. I also draw your attention to our disclaimer. We will be making certain forward-listing statements that are based on the knowledge we have today. I will start this conference call by giving a quick overview of our recent activities and achievements before reviewing our pipeline. I will then hand over to Misha, who will review in more detail our GABA-B, HAM, preclinical program for COFF. I will then review our financial results. Following that, we will open the call for questions. The first half of 2025 has seen several important achievements across our pipeline. We've made excellent progress in our GABA v. PAM program with our partner Indivior successfully completing IND-enabling studies with their selective drug candidate su...